Home
Issues
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
2021
December - Vol 14, No 4
September - Vol 14 No 3
June - Vol 14, No 2
March - Vol 14 No 1
2020
October/November - Vol 13 No 5
September - Vol 13 No 4
June - Vol 13 No 3
May - Vol 13 No 2
February - Vol 13 No 1
Issue Archive
Value-Based Care in Cardiometabolic Health
Special Issues
2021 Special Issues
December - Twelfth Annual Payers' Guide
August - Vol 14, Special Issue: Payers' Perspectives in Oncology
February - Vol 14, Special Issue: Payers' Perspectives in Oncology
2020 Special Issues
Supplements
Special Issue Archive
Topics
Conference Correspondent
ASCO 2020 - Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
2021
December - Vol 14, No 4
September - Vol 14 No 3
June - Vol 14, No 2
March - Vol 14 No 1
2020
October/November - Vol 13 No 5
September - Vol 13 No 4
June - Vol 13 No 3
May - Vol 13 No 2
February - Vol 13 No 1
Issue Archive
Value-Based Care in Cardiometabolic Health
Special Issues
2021 Special Issues
December - Twelfth Annual Payers' Guide
August - Vol 14, Special Issue: Payers' Perspectives in Oncology
February - Vol 14, Special Issue: Payers' Perspectives in Oncology
2020 Special Issues
Supplements
Special Issue Archive
Topics
Conference Correspondent
ASCO 2020 - Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Medical Writer
Authored Items
Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals
Caroline Helwick
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Drug Updates
,
FDA Approvals
,
Payers' Guide
Searching for the Tipping Point in Drug Pricing
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Oncology Pipeline Full, and Not Just with Immunotherapies
Caroline Helwick
,
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Aetna Examines Impact of Site of Service on Chemotherapy Cost
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Researchers Dissect the Cost of Targeted Agents
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Will Necitumumab Be Cost-Effective?
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
UnitedHealthcare’s Episode-Based Payment Model Program Cuts Cost
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Bundling Payments: UnitedHealthcare Dips a Toe in the Water
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Novel Rosacea Compound, Ivermectin Cream, Offers Unique Mechanism of Action
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Ivermectin Cream Will Contribute Much to the Treatment of Patients with Rosacea: Interview with Dr Zoe Draelos
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Addressing an Unmet Need in the Treatment of Patients with Papulopustular Rosacea: An Interview with Dr Linda Stein Gold
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Investigational Agent Clears Papulopustular Rosacea by Tackling an Underlying Cause
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Less May Be “More” with Zoledronic Acid
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Breast Cancer
Novel Drug Classes Make News in Multiple Myeloma
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Multiple Myeloma
Site of Service Influences Value
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Value-Based Insurance Not Such an Easy Sell
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
What Makes a Treatment Clinically Meaningful?
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
ASCO Beginning to Address Value in Oncology
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Ramucirumab Shows Survival Benefit in NSCLC
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Lung Cancer
Anti–PD-1 Antibodies for NSCLC and Renal Carcinoma
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Emerging Therapies
Enthusiasm Sky High for Immunotherapy with Anti–PD-1 Agents in Cancer
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Emerging Therapies
Generic Docetaxel Increases Risk of Neutropenia, Costs
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Financial Distress Experienced by 40% of Patients with Cancer
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
ASCO Workgroup Proposes Consolidated Payments
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
2014 Oncology Pipeline Looks Impressive
Caroline Helwick
,
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Emerging Therapies
Ibrutinib Outperforms Ofatumumab in Patients with Relapsed/Refractory CLL
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Leukemia
The Social Impact of Rosacea, Patterns of Care, and Associated Costs Featured at AAD 2014
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
AAD 2014 Highlights: Understanding Inflammation Markers and Treating Erythema in Rosacea
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Rosacea: A Multifaceted Skin Disorder
Caroline Helwick
Payer Perspectives in Dermatology
Introduction to Rosacea: An Underrecognized and Undertreated Medical Condition
Caroline Helwick
Payer Perspectives in Dermatology
More Transplants Made Possible Through Haploidentical Donors
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Conference Highlights ASH
Rituximab Maintenance Extends Remission in Follicular Lymphoma, but Overall Survival Unaffected
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Lymphoma
PI3K Inhibitors Main Focus of Drug Pipeline for Lymphoma
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Lymphoma
Myeloma Drug Arsenal Expanding to New Classes
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Multiple Myeloma
Lenalidomide Maintenance in Transplant-Eligible Myeloma Population Still Debated
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Multiple Myeloma
FIRST Trial Shows Value for Continued Use of Lenalidomide in Transplant-Ineligible Patients with Newly Diagnosed Myeloma
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Multiple Myeloma
Novel CAR-T Therapy Topped the News at ASH 2013
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Hematologists Urged to Reduce Unnecessary Tests/Procedures, and Costs to Improve Quality of Care
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Hematologists Often Ignore Treatment and Monitoring Recommendations
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Cost and Drug Utilization Patterns Associated with the Management of Rosacea
Caroline Helwick
November/December 2013, Vol 6, No 9
in
Industry Trends
Cost and Drug Utilization Patterns Associated with the Management of Rosacea
Caroline Helwick
Payer Perspectives in Dermatology
Skin Disorders the Number One Reason for Medical Visits in the United States
Caroline Helwick
Payer Perspectives in Dermatology
Emerging Therapies for the Treatment of Rosacea
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
in
Health Policy and Reform
Two Surveys Confirm Drug Shortages Are a Persistent Problem, Increasing Costs
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Routine Surveillance CT Costly, Unnecessary in Lymphoma in Remission
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Assessing the Value of New, Costly Radiation Therapies in Older Patients with Breast Cancer
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Can We Afford to Make Progress in Cancer Care?
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Do Financial Incentives Drive Physician Behavior?
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Off-Label Drug Use in Oncology Accounts for 18% of Spending
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Cancer Drug Pipeline Is Bustling
Caroline Helwick
,
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Rosacea: A Misunderstood, Serious Medical Condition
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Current Therapies for the Management of Patients with Rosacea
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Redness in Rosacea: Still an Unmet Medical Need
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Face to Face with Rosacea
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Investing in Information Technology Pays Off: Meaningful Use Stage 1 Met by Majority of US Hospitals
Caroline Helwick
March/April 2013 Vol 6, No 2
in
Industry Trends
Payer Perspective: Reimbursement Obstacles Prevent Effective Treatment of Rosacea
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Rosacea Management: A Conversation with Dr Guy Webster
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Anti-Inflammatory–Dose Doxycycline Is Equally Effective in Men and Women with Rosacea
Caroline Helwick
Payer Perspectives in Dermatology
in
Rosacea
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
in
Multiple Myeloma
Host Factors Important in Patients with Myeloma
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
in
Multiple Myeloma
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
in
Multiple Myeloma
Bendamustine plus Rituximab Noninferior to Standard Chemotherapy for Indolent Non-Hodgkin and Mantle-Cell Lymphomas
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
in
Lymphoma
Rivaroxaban More Cost-Effective than Warfarin for Recurrent VTE Prevention
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Costs of Second-Line Metastatic Colorectal Cancer Treatments Compared
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Rasburicase Cost-Effective for Tumor Lysis Syndrome
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Faster Rituximab Infusion Lowers Cost
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Hematologic Drug Pipeline Is Bustling
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Azacitidine Reduces Transfusions and Costs for Patients with High-Risk MDS
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Chemotherapy-Related Toxicity Adds to Economic Burden in Metastatic Breast Cancer
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Breast Cancer
Pomalidomide Shows Strong Activity in Relapsed/Refractory Myeloma
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Multiple Myeloma
Molecular Profiling Guiding Cancer Therapy
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Crizotinib Effective in Aggressive Pediatric Tumors
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Pediatric Cancer
The Oncology Drug Pipeline Robust with Novel Agents
Caroline Helwick
,
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Pipeline
The Cost of Lung Cancer at the End of Life: Early Institution of Palliative Care Improves Survival
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Why Hasn’t Genomic Testing Changed the Landscape?
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Metastatic Colorectal Cancer: Prolonged Bevacizumab Improves Outcomes, New Targeted Therapies on the Horizon
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Is Biomarker Testing in NSCLC Cost-Effective?
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Patient Adherence Rises with Cost of Oral Cancer Drugs
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Is Plerixafor Cost-Effective for Stem-Cell Mobilization?
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
Caroline Helwick
,
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Leukemia
VISTA Final Analysis Upholds Survival Benefit of Bortezomib at 5 Years
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Multiple Myeloma
,
Multiple Myeloma
Maintenance Strategies in Elderly Patients with Myeloma Not Eligible for Transplant
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Multiple Myeloma
,
Multiple Myeloma
Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
High Morbidity Burden Borne Years Later by Survivors of Transplant
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Conference Highlights ASH
Maintenance Rituximab May Be Unnecessary in FL
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Leukemia
Radiologic Surveillance for Early-Stage Hodgkin Lymphoma an Unnecessary Expense?
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
A Large Study Sheds Light on the Cost of Managing NHL
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
Hematologic Pipeline Abundant
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
VTE Prophylaxis during Chemotherapy Cost-Effective
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Conference Highlights ASH
Next-Generation Proteasome Inhibitors Cause Less Peripheral Neuropathy
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Multiple Myeloma
,
Multiple Myeloma
Genetic Profiles Linked to Hematologic Outcomes
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Conference Highlights ASH
Future Directions in Myeloma
Caroline Helwick
,
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
in
Multiple Myeloma
,
Multiple Myeloma
Drug Shortages the “New” Old Problem: People Are (Finally) Talking
Caroline Helwick
November/December 2011, Vol4, No7
in
Industry Trends
Can Episode Payments Reduce Cost and Maintain Quality Cancer Care?
Caroline Helwick
July/August 2011, Vol 4, No 4
Value of Targeted Therapies in Patients Lacking a Molecular Target Questioned
Caroline Helwick
August 2011 Vol 4, No 4, Special Issue
Optimal Length of Treatment of Non-Hodgkin Lymphoma Debated
Caroline Helwick
August 2011 Vol 4, No 4, Special Issue
in
Lymphoma
Financial Incentives Encourage Patients to Choose Less Expensive Regimens
Caroline Helwick
August 2011 Vol 4, No 4, Special Issue
Novel Approaches to Therapy in the Oncology Pipeline
Caroline Helwick
August 2011 Vol 4, No 4, Special Issue
in
Pipeline
US Provider Practices Bracing for Change: New Survey Results
Caroline Helwick
Web Exclusives
Promising Oncology Drugs in the Pipeline
Caroline Helwick
Web Exclusives
in
Pipeline
Oncologists Cautioned About Use of ESAs
Caroline Helwick
Web Exclusives
Anticancer Drug Development Trends: Translational Medicine
Caroline Helwick
May 2008, Vol 1, No 4
Paying for Cancer Care: Economic Models Start to Emerge, Dovetailing Healthcare Reform
Caroline Helwick
April/May 2009, Vol 2, No 3
in
Industry Trends
NCCN Panel Debates the Economics of Cancer Care
Caroline Helwick
March/April 2010, Vol 3, No 2
in
Conference Highlights NCCN
PET Scans Not Recommended for Most Patients with Breast Cancer: Potential New Controversy in Breast Cancer Testing
Caroline Helwick
March/April 2010, Vol 3, No 2
in
Conference Highlights NCCN
Emerging Trends in Breast Cancer Management
Caroline Helwick
January/February 2010, Vol 3, No 1
in
Industry Trends
New Approaches to Treating HCV Infection
Caroline Helwick
May/June 2010, Vol 3, No 3
in
Conference Highlights Digestive Disease Week
Last modified: March 14, 2014
SUBSCRIBE
HOME
ABOUT
CONTACT US
TERMS OF USE
PRIVACY POLICY
ADVERTISING POLICY
Copyright © Amplity Medical Communications. All rights reserved.
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
AHDB
Print Edition
AHDB
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
AHDB
's
Privacy Policy
, and
AHDB
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION
